Five variants of Botulax, Hugel's botulinum toxin product line. [Hugel]
Five variants of Botulax, Hugel's botulinum toxin product line. [Hugel]

South Korea's leading aesthetics companies are moving away from their traditional reliance on a single flagship product — whether botulinum toxin or skin boosters — and accelerating the buildout of full-spectrum portfolios spanning fillers, dermacosmetics and health supplements.

Strategic diversification aimed at overcoming intensifying price competition in the domestic market and strengthening bundled sales to medical professionals in global markets is emerging as the core engine of earnings growth.

Hugel, the first among its peers to report confirmed first-half results, offered the clearest proof of what portfolio diversification can deliver. The company posted consolidated sales of 254.5 billion won ($179 million) and operating profit of 103.7 billion won in the first half of this year, setting a new record for any half-year period in its history.

Botulinum toxin, its flagship product, drove growth with sales of 149.4 billion won, while the hyaluronic acid filler and skin booster segment contributed 66.1 billion won and the cosmetics and other segment surged 31.7 percent year-on-year to 39 billion won. Non-toxin products now account for 41.3 percent of total sales, cementing Hugel's position as a diversified aesthetics company.

Hugel's strong growth reflects a strategy built on cross-product synergies at home and abroad. In South Korea, the company has reinforced its market dominance through bundled sales linking toxin and filler products. Overseas, it has expanded supply across its full aesthetics lineup, with Europe and the Americas as the primary focus. In the United States particularly, Hugel has made early investments in building a direct-sales distribution network through its local subsidiary, Hugel America, pursuing both tighter distribution margins and a more refined clinic and hospital network simultaneously.

Rejuvi-S Ampoule, a cosmeceutical product sold through pharmacies. [PharmaResearch]
Rejuvi-S Ampoule, a cosmeceutical product sold through pharmacies. [PharmaResearch]

PharmaResearch, the leader in the skin booster market, is also pushing aggressively to expand its pipeline. The company recorded consolidated first-quarter sales of 146.1 billion won, with its medical device business — centered on Rejuran, a facial aesthetics device derived from salmon-origin PN ingredients — contributing 79.5 billion won, or 54.5 percent of the total, and its cosmetics business, including the Rejuran Cosmetic line, adding 42.2 billion won, or 29.0 percent. Together, the two aesthetics segments account for 83.5 percent of total sales.

PharmaResearch has successfully extended the Rejuran brand from medical devices into a skin-efficacy-focused cosmetics line, significantly broadening its direct-to-consumer reach. The company has also obtained domestic product approval for Rientox, a botulinum toxin formulation developed through its subsidiary Pharmaresearch BIO, and has begun full-scale sales — a reverse territorial expansion into the toxin market. With that move, PharmaResearch has completed an aesthetics triangle of toxin, skin booster and cosmetics.

Nuviju, an injectable treatment for moderate to severe submental fat. [Medy-Tox]
Nuviju, an injectable treatment for moderate to severe submental fat. [Medy-Tox]

Medy-Tox, which has long relied on botulinum toxin and its HA filler Neuramis as its twin pillars, is significantly broadening its reach across the beauty and healthcare space. In the first quarter, toxin and filler accounted for 61.5 percent and 26.0 percent, respectively, of the company's 60.7 billion won in sales.

Medy-Tox launched Nuviju, a cholic acid-based fat-reduction injectable that became South Korea's 40th domestically approved new drug, as it seeks to establish a foothold in that market. The company also signed a supply agreement to place its dermacosmetics brand Neuraderm in more than 60 stores across Hong Kong and Macao. It also entered the diet probiotic market with the launch of Lactiplan, a probiotic supplement formulated with a functional ingredient clinically shown to reduce body fat.

Building a platform that cross-sells an entire aesthetics lineup — rather than depending on a single product — is widely seen as the key growth formula for improving global margins and reinforcing a premium corporate valuation.

"At aesthetics clinics around the world, demand is growing for packaged offerings that combine toxin, filler, skin boosters and post-procedure skincare products," an industry official said. "Companies that have diversified their product lineup will find themselves in a stronger negotiating position with local distributors."


silverpaper@heraldcorp.com